Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant
Background
Human herpesvirus-6B (HHV-6B) encephalitis is a severe complication following cord blood transplantation (CBT), with a reported incidence of 7.5% in this study. The disease carries high mortality and morbidity, yet optimal antiviral management remains controversial. This registry-based study from Japan provides critical real-world evidence on the impact of different antiviral regimens—foscarnet (FCN) monotherapy, ganciclovir (GCV) monotherapy, and FCN/GCV combination therapy—on survival outcomes.
Study Design
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.